All In Biotech

Drug Trial Radar · NCT07362992

Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery

Does Topical Use of Tranexamic Acid During a Cesarean Delivery Reduce Intra-surgical Bleeding? A Randomized ,Multi-center Trial

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Dec 1, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Wolfson Medical CenterGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Rabin Medical Center; Meir Medical Center; Kaplan Medical Center
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 51 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more). The main questions it aims to answer are: * Does topical TXA shorten uterine closure time? * Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes. Participants will: * Be randomly assigned to receive either topical TXA or placebo during cesarean delivery. * Have standard surgery and postoperative care identical in both groups. * Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.

Conditions

  • Cesarean Delivery
  • Postpartum Hemorrhage (PPH)
  • Intraoperative Blood Loss
  • Hemostasis

Interventions

  • Tranexamic Acid (Topical)Drug

    This intervention involves topical application of tranexamic acid (TXA) directly to the uterine incision during cesarean delivery, rather than the conventional intravenous route. A solution containing 500 mg of TXA (one ampule, 5 mL) diluted in 15 mL of normal saline is sprayed evenly over the uterine incision surface after placental delivery and before suturing. A second application of the same solution is sprayed before the second layer of uterine closure. This localized, site-directed use is designed to reduce intraoperative bleeding with minimal systemic absorption, distinguishing it from previously studied intravenous TXA regimens.

  • Normal Saline (Placebo)Other

    This comparator intervention involves topical application of sterile normal saline to the uterine incision at the same time points as in the TXA arm - after placental delivery and before each layer of uterine closure. This placebo control enables a direct comparison to determine whether the topical TXA application provides added benefit in reducing intraoperative bleeding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Uterine closure time (minutes)Time frame: Intraoperative (during the index cesarean delivery)
  2. Number of additional hemostatic sutures (count)Time frame: Intraoperative (during the index cesarean delivery)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Meir medical center

    Kfar Saba, Israel · Not yet recruiting

  • Rabin medical center

    Petah Tikva, Israel · Not yet recruiting

  • Kaplan medical center

    Rehovot, Israel · Not yet recruiting

  • Edith Wolfson Medical Center

    Holon, Central District, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.